Coloplast reported mixed Q2/H1 2021 numbers. Sales were up 2% on an organic basis, driven by ostomy (+4%) and urology (+3%). Adjusted EBIT was up 2% with the associated margin at 33% (+100bp).
FY21 top-line growth outlook was maintained (7-8% organic, 4-5% in DKK), while the adjusted EBIT margin is now expected at 32-33% (vs 31-32% earlier).
We do not expect any significant changes to our estimates, as we believe the soft Q2 showing should be offset by stronger H2 growth.
Companies: Coloplast A/S Class B (COLO.B:CSE)Coloplast (COLO-B:CPH)
Coloplast announced good Q1 21 numbers, even though it missed our estimates. Revenue was up 5% on an organic basis, driven by chronic care (+5%) and urology (+5%), which offset soft wound & skin (+1%). Adjusted EBIT came in at DKK1.5bn with the margin at 32% (+100bp).
FY21 outlook remains unchanged with 7-8% top-line growth and a 31-32% EBIT margin.
Factoring in the marginal miss vs our estimates, we will trim our estimates accordingly, with little impact on the target price.
Companies: Coloplast A/S Class B
Coloplast reported mixed Q4 20 numbers – missing revenue estimates and beating on profits. Sales were up 2% to DKK4.6bn – driven by ostomy and continence – while the EBIT margin was unchanged at 32%. The board proposed a final dividend of DKK13/share. For FY21, management expects top-line growth of 7-8% and an EBIT margin of 31-32%, largely in line with estimates. Following the largely expected performance, we do not expect any significant changes in our estimates/recommendation.
Coloplast reported soft Q3 20 numbers as sales declined 2% on an organic basis, while the EBIT margin came in at 31%. The softness was driven by a 40%/6% decline in Urology/Wound & Skin, which more than offset the 4% growth in chronic care. The company lowered FY20 growth expectations (4% vs 4-6% earlier) while increasing the EBIT margin guidance to 31% (vs 30-31% earlier). We will be lowering our estimates to factor in the soft performance.
Coloplast reported strong Q2 20 numbers. Sales (driven by chronic care) rose 9% on an organic basis, with the EBIT margin at 32% (+1pp due to operating leverage and cost-cutting). The company announced a dividend of DKK5/share and re-iterated FY20 expectations (4-6% topline growth, 30-31% EBIT margin). Capex will be increased to DKK950m (vs DKK 850m earlier), in order to boost production. In anticipation of unwinding stockpiling effects, we do not expect any significant changes to our estimates.
Coloplast announced good Q1 20 numbers – trumping estimates on both the topline and bottomline. Sales were up 8% on an organic basis – driven by wound and skin care (+10%), ostomy (+9%), urology (+9%) – and the EBIT margin came in at 31%. Management re-iterated its FY 2020 guidance: topline growth of 7-8%, EBIT margin at ~31%, capex around DKK850m and an effective tax rate of nearly 23%. Following the Q1 numbers, we will be making minor upward revisions in our estimates.
Coloplast reported mixed Q4 19 numbers – in line revenue and a miss on the bottom-line. Sales were up 8% on an organic basis, led by strong growth in Urology (+11%), while the EBIT margin came in at 32%. For FY 20, management expects 7-8% organic top-line growth and an EBIT margin of ~31% at CER with a neutral FX impact. Following the largely in line performance, we do not expect any major changes in our estimates.
Coloplast reported Q3 19 numbers in line with consensus as well as our estimates. Sales were up 8% on an organic basis, driven by broad-based growth across segments, while the EBIT margin came in at 31%. Management re-iterated its FY 2019 expectations: organic growth of ~8% (reported growth of ~9%) and an EBIT margin of 30-31% at CER (~31% reported). Following the largely in line performance, we do not expect any major change in our estimates.
Coloplast reported Q2 19 numbers in line with consensus but marginally above our estimates. Sales were up 8% on a CER basis – driven by urology, continence care and wound care – while the EBIT margin came in at 30.5%. Management re-iterated its FY 2019 growth expectation of ~8% at CER but upgraded reported growth expectations (~9% vs 8-9% earlier). The EBIT margin expectations remain unchanged (30-31% CER; ~31% reported). Following the largely in line numbers, we do not expect any major change i
Coloplast reported mixed Q1 19 numbers – meeting top-line estimates and marginally missing on profitability. Sales grew by 8% – with all segments reporting strong growth. The EBIT margin contracted marginally and came in at 30.4%. FY2019 guidance was maintained. Following the largely in line performance, we do not expect any major change to our estimates or rating.
Coloplast missed the street’s estimates across the board in Q4 18, but largely met our rather conservative estimates. Sales grew by 8% – a strong urology and ostomy performance was partly offset by a mixed performance in wound and skin care. The EBIT margin – helped by margin expansion in urology and wound care – came in above expectations at 31.3%. In spite of the decent Q4, a possibility of further reform headwinds in 2019 keep our estimates and rating largely unchanged.
Coloplast’s Q3 18 top-line came in better than our expectations but missed the street’s expectations by a whisker. The bottom-line, on the other hand, lagged ours as well as the street’s estimates. Wound care and urology reported a sequential acceleration while chronic care (continence and ostomy), even though delivered another quarter of market-beating growth, wasn’t better sequentially. Factoring in the Q3 numbers, we will make minor tweaks to our estimates, but we do not foresee any significa
Coloplast’s Q2 2018 results came in above our estimates on the top line while under-performing our bottom-line estimates. Segment-wise, Ostomy and Continence care maintained momentum, Wound Care bounced back while Skin Care disappointed. The company remained confident of the current investment and cost rationalisation efforts paying off from 2019-20. We have nudged up our long-term margin estimates and forecasts, but maintain a reduce recommendation, and believe that the recent rally has been t
Coloplast’s Q1 18 results came in slightly below expectations, at both the top-line as well as the bottom-line. The strength in the Ostomy and Continence care segments was offset by weakness in wound care. We have tweaked our numbers based on the Q1 results and the Lilial acquisition, but maintain our recommendation on the stock.
Following a weak Q3 17 (hit by a DKK90m charge attributable to miscalculations related to the US Veterans Affairs contract in 2009), Coloplast ended the year on an underwhelming note, with Q4 17 results coming in slightly below consensus expectations (1.3% and 0.4% miss on the top-line and profitability, respectively). On a reported basis, sales grew 6% to DKK3,980m, incorporating an 8% organic and 1% acquisitive expansion (acquisition of Comfort Medical), offset by currency headwinds of 3% (USD
Research Tree provides access to ongoing research coverage, media content and regulatory news on Coloplast A/S Sponsored ADR.
We currently have 0 research reports from 0
OptiBiotix has reported its final results for the year to December 2020, which are largely in-line with the financials reported with the recent ‘Strategy and commercial update'. 2020 was a strong year for the company as its two operational divisions achieved EBITDA profitability supported by increased commercialisation of the group's product range. This commercial moment has continued into 2021, as the company looks to scale its first-generation product sales with new product lines and new terri
Companies: OptiBiotix Health PLC
Venture Life has announced it has entered into a Revolving Credit Facility (RCF) with Santander UK and Silicon Valley Bank. The funds, of up to £50m, provide leverage to the company's existing cash resources, and will support management's M&A ambitions, following the recent acquisition of BBI Healthcare for c£36m. We remain encouraged by Venture Life actively progressing its overall M&A strategy, which we expect to scale the company and provide operational leverage opportunities to maximise the
Companies: Venture Life Group Plc
CareTech is a specialist social care and educational services provider. This morning, the group has announced interim results to 31 March 2021, which illustrate another positive six month period, particularly when considering the present wider backdrop. An increase in underlying PBT of 31.6% against the prior year benefited from organic growth, as well as the acquisition of Smartbox, transfer in of The Huntercombe Group facilities and a full period contribution from the Middle East. As reported
Companies: CareTech Holdings PLC
As midsummer’s day looms (where has this year gone?), there is greater optimism, in general, than may have been anticipated a few months ago. A post-pandemic, ‘vaccine-driven’ recovery demonstrated by increased consumer spending as lockdown measures are lifted has been one of the catalysts. The FTSE 100 has been range-bound in the last month 6,900-7,100. We have seen a combination of broadly positive company results across a range of sectors, further examples of M&A activity and a sequence of ne
Companies: AMYT ARBB ARW BAG BEG BONH BWNG CWK DNK EML EPWN FBD FA/ GPH GSF GNC HUW IGC INSE KAPE KP2 MMAG NRR NESF OTMP ROL RUA SEN SUR TON TOU TXP TGL VLS WINK
In this week’s edition of Liberum's Podcast - Best Idea of the Week, Ed Blair talks to Graham Doyle of Liberum's Healthcare team to discuss his recent sector note. Graham explains why UK Healthcare is likely to face macro headwinds over the next six months, why Medica and PureTech are the Top Picks during this period and why there may be an opportunity from a lagging reopening trade in healthcare.
Companies: Medica Group Plc (MGP:LON)PureTech Health PLC (PRTC:LON)
VLG has agreed a new £30m RCF (with a further £20m available subject to certain conditions). This provides significant additional low-cost funding to continue its growth strategy, including accretive acquisitions. With an exciting pipeline of opportunities, and a strong track record of delivery (including realisation of synergies), this news should be well received. In the first full year of earnings and synergy from its most recent BBIH acquisition, the EV/EBITDA multiple is currently just 10x
Calnex Solutions has announced record results for FY21 following customer orders up across all product types and within all regions, with FY21 revenue up 31% to £18.0m and adjusted PBT up 43% to £5.1m. Calnex has firmly established a trusted reputation worldwide, launching multiple first to market telecoms and network testing solutions. Calnex continues to accelerate its investment in R&D and expand its product roadmap, adding increased engineering, sales and customer support capacity in order t
Companies: Calnex Solutions Plc
There has been a safety halt to the lead human retinal progenitor cell (hRPC) project. The issue was an eye infection in one patient following a successful surgical implantation of the hRPC. The cause is under investigation. If, as we assume, the trial restarts in the next few months, data should be available by Q421, a delay of perhaps three months. This is not significant within the overall developmental pathway and good data are needed to secure any future partnership from mid-2022. The valua
Companies: ReNeuron Group plc
SUN’s AGM statement paints a picture of a business recovering well after the challenges posed by the pandemic. It has successfully won new accounts in the UK and US on the back of its strong environmental and health economic credentials. These look to be increasingly resonating and are laying the foundations for a powerful growth story as elective surgery volumes recover. This should be sustained into the medium term as healthcare systems around the world look to reduce waiting times, costs and
Companies: Surgical Innovations Group plc
SDI Group has published a second positive trading update ahead of July’s FY21E results announcement. Management’s guidance for revenue and adjusted PBT is approximately £35.3m and £7.4m respectively, ahead of our previous FY21E estimates (and previous guidance) of £34.0m and £6.7m. We upgrade our FY21E forecasts accordingly, with a 10% uplift to our fully adjusted PBT forecast. Current base guidance for FY22E remains unchanged with revenue of £42m and adjusted PBT of £8.7m. Consequently, we are
Companies: SDI Group plc
In an encouraging sign of building US momentum, Yourgene has announced it has signed a multi-year licence and supply agreement with a major US precision medicine company to enable it to offer a new reproductive health screening service from its own laboratories. The agreement encompasses a non-exclusive licence to Yourgene’s proprietary bioinformatics Flex analysis software and a supply agreement for sample preparation reagents and instrumentation. Notably, this includes the Ranger sample enrich
Companies: Yourgene Health Plc
Belluscura is a medical device company focused on developing lightweight and portable oxygen enrichment technology. The group completed its IPO in June, raising £17.5m at a price of 45p. Following IPO, the group has appointed a VP of Operations and this morning has confirmed its first US distribution deal. On 15th June, the group announced the appointment of Keith Cook as Vice President of Operations, based in Plano, Texas. Keith was previously Director of Operations at Inogen, the market leader
Companies: Belluscura PLC
Calnex Solutions is a leading provider of test and measurement hardware and software solutions that enable performance validation and standards conformance of critical infrastructure associated with telecoms and high-speed data networks. 5G network evolution is a significant, long-term driver of growth for the business along with the continued expansion of hyperscale datacentre enterprises and their increasing participation in telecoms infrastructure markets. Calnex has established a trusted rep
Half-year results to December 2020 reflect a period in which genedrive has made notable strides, but also reflect frustrating delays in commercialising its products, largely due to factors outside of its control. genedrive generated revenues of £0.4m in the half-year (2019: £0.6m, -43%), with an adjusted net loss of £2.9m (2019: -£2.8m, -3%) with cash of £3.8m at the end of the period. genedrive remains hopeful for FDA emergency use authorisation (EUA) for Genedrive 96® SARS-CoV-2 and remains in
Companies: Genedrive Plc
The UK market showed a continued recovery in the first quarter albeit the indices are still well short of their all-time peaks, unlike many of their international peers. The FTSE 100 has risen by 1,186 points (21.4%) since the end of October and the FTSE 250 by 4,304 points (25.0%). The comparable performance since the start of the year is less spectacular- the FTSE 100 has risen by 253 points (3.9%) and the FTSE 250 has risen by 1,070 points (5.0%). The factors behind the sustained rally are fa
Companies: AMYT ARBB CEG BAG BVC BEG BONH BLVN BRSD CML CWK CRPR EYE ECHO FDM FAR FA/ GPH GSF HUW INSE JDG KAPE KP2 MACF MPAC MNZS NESF NBI OTMP OBD PREM QFI RUA SCS SEN SOS SUR TON TOU TXP TGL TCN UEM VLS WYN